Pegtarazimod reduces brain inflammation, says new study data
A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
The article in the American Journal of Perinatology highlights that pegtarazimod reduces the levels of resident microglia as well as the neuroinflammatory factors myeloperoxidase (MPO) and reactive oxygen species (ROS) in the brains of HIE animals.
While microglia are essential for maintaining brain homeostasis and mediating tissue repair, the presence of extracellular MPO in the brain activates microglia to an overactivated, pro-inflammatory state, leading to the formation of extracellular traps that further contribute to tissue damage.
These preclinical findings build upon Phase II STAR trial clinical biomarker data, which demonstrated elevated levels of MPO in newborns with HIE, with generally higher levels observed in severe versus moderate cases.
“These new data further support pegtarazimod’s potential to address neuroinflammation in the brain by reducing detrimental microglial-mediated inflammation,” said Kenji Cunnion, Chief Medical Officer at ReAlta. “The mechanistic validation of pegtarazimod translating from preclinical models to the clinical biomarker findings in our STAR trial reinforces our confidence in our dual-targeting peptide platform’s ability to interrupt this damaging inflammatory cascade.
“We expect to report an interim clinical data readout in the second half of 2025 and look forward to exploring additional opportunities to deliver effective new therapies for neurological diseases, where significant unmet medical needs remain.”
Preclinical studies of pegtarazimod
In the preclinical study, pegtarazimod treatment decreased microglial recruitment by fourfold compared to controls at 48 hours and significantly reduced MPO staining, a key driver of oxidative brain damage.
Pegtarazimod treatment also resulted in 6% greater neuron density compared to hypothermia treatment alone, while demonstrating anti-inflammatory effects equivalent to therapeutic hypothermia, the current standard of care for HIE.
Dr Zachary Vesoulis, Assistant Professor of Pediatrics, Newborn Medicine at Washington University School of Medicine and co-author of the study, commented: “Pegtarazimod’s ability to reduce brain inflammation in this pre-clinical model demonstrates the potential of this drug to improve clinical outcomes for HIE babies, for which there is currently no pharmacological intervention.”
Diana Turner, Senior Digital Content Editor, DDW
